| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| von Willebrand Factor | 55 | 2024 | 196 | 7.900 |
Why?
|
| Blood Platelets | 30 | 2023 | 327 | 2.760 |
Why?
|
| Thrombosis | 13 | 2022 | 522 | 2.610 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 27 | 2022 | 39 | 2.320 |
Why?
|
| Vimentin | 5 | 2022 | 66 | 2.060 |
Why?
|
| Platelet Adhesiveness | 14 | 2019 | 40 | 1.980 |
Why?
|
| Fibrin | 5 | 2024 | 65 | 1.560 |
Why?
|
| Endotoxemia | 3 | 2024 | 58 | 1.350 |
Why?
|
| P-Selectin | 3 | 2020 | 78 | 1.290 |
Why?
|
| Membrane Glycoproteins | 8 | 2020 | 411 | 1.280 |
Why?
|
| Recombinant Proteins | 24 | 2021 | 1394 | 1.240 |
Why?
|
| Collagen | 10 | 2022 | 316 | 1.130 |
Why?
|
| ADAMTS13 Protein | 15 | 2024 | 62 | 1.060 |
Why?
|
| Platelet Activation | 9 | 2021 | 71 | 1.000 |
Why?
|
| Disseminated Intravascular Coagulation | 4 | 2021 | 67 | 0.950 |
Why?
|
| Endothelium, Vascular | 7 | 2021 | 523 | 0.940 |
Why?
|
| Cell Adhesion | 8 | 2020 | 321 | 0.900 |
Why?
|
| Protein Binding | 30 | 2020 | 1749 | 0.900 |
Why?
|
| Platelet Aggregation | 11 | 2016 | 121 | 0.890 |
Why?
|
| Hemostatics | 1 | 2022 | 57 | 0.790 |
Why?
|
| Leukocytes | 2 | 2020 | 206 | 0.780 |
Why?
|
| Thromboembolism | 2 | 2022 | 90 | 0.750 |
Why?
|
| von Willebrand Diseases | 6 | 2022 | 51 | 0.750 |
Why?
|
| Protein Structure, Tertiary | 21 | 2015 | 757 | 0.740 |
Why?
|
| Peptide Fragments | 5 | 2021 | 779 | 0.690 |
Why?
|
| Binding Sites | 15 | 2024 | 1297 | 0.620 |
Why?
|
| Sepsis | 1 | 2022 | 479 | 0.560 |
Why?
|
| Hemoglobins | 2 | 2015 | 303 | 0.560 |
Why?
|
| Metalloendopeptidases | 4 | 2004 | 100 | 0.540 |
Why?
|
| Critical Illness | 6 | 2022 | 600 | 0.510 |
Why?
|
| Neutrophils | 1 | 2018 | 379 | 0.490 |
Why?
|
| ADAM Proteins | 10 | 2015 | 78 | 0.480 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 4 | 2021 | 85 | 0.460 |
Why?
|
| Shear Strength | 1 | 2014 | 17 | 0.450 |
Why?
|
| Platelet Membrane Glycoproteins | 9 | 2013 | 31 | 0.450 |
Why?
|
| Inflammation | 6 | 2024 | 1430 | 0.400 |
Why?
|
| Thrombelastography | 3 | 2021 | 57 | 0.390 |
Why?
|
| Hemodynamics | 1 | 2015 | 850 | 0.370 |
Why?
|
| Humans | 68 | 2024 | 124802 | 0.360 |
Why?
|
| Stress, Physiological | 1 | 2012 | 257 | 0.340 |
Why?
|
| Integrins | 2 | 2000 | 82 | 0.330 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 5 | 2016 | 61 | 0.320 |
Why?
|
| Fibrinogen | 4 | 2022 | 153 | 0.320 |
Why?
|
| Protein Domains | 5 | 2021 | 234 | 0.320 |
Why?
|
| Stress, Mechanical | 7 | 2018 | 171 | 0.320 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 4431 | 0.320 |
Why?
|
| Kinetics | 10 | 2019 | 1325 | 0.310 |
Why?
|
| Animals | 24 | 2024 | 34200 | 0.300 |
Why?
|
| Protein Conformation | 8 | 2021 | 833 | 0.300 |
Why?
|
| Disease Models, Animal | 5 | 2024 | 4359 | 0.290 |
Why?
|
| Fibrinolysis | 3 | 2022 | 40 | 0.280 |
Why?
|
| Protein Structure, Secondary | 4 | 2019 | 238 | 0.270 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2019 | 154 | 0.270 |
Why?
|
| Integrin alpha2beta1 | 2 | 2005 | 7 | 0.250 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2021 | 374 | 0.250 |
Why?
|
| Ristocetin | 7 | 2012 | 8 | 0.240 |
Why?
|
| Mice | 11 | 2024 | 17757 | 0.240 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 359 | 0.230 |
Why?
|
| von Willebrand Disease, Type 3 | 1 | 2024 | 6 | 0.230 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 375 | 0.230 |
Why?
|
| In Vitro Techniques | 7 | 2019 | 973 | 0.230 |
Why?
|
| Multiprotein Complexes | 3 | 2016 | 207 | 0.220 |
Why?
|
| Hemostasis | 2 | 2023 | 69 | 0.220 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2024 | 153 | 0.220 |
Why?
|
| Models, Molecular | 8 | 2009 | 1075 | 0.210 |
Why?
|
| Citrulline | 1 | 2024 | 107 | 0.210 |
Why?
|
| Polyethylene Glycols | 1 | 2024 | 223 | 0.210 |
Why?
|
| Aspartic Acid | 1 | 2003 | 75 | 0.210 |
Why?
|
| Extracellular Space | 1 | 2022 | 88 | 0.210 |
Why?
|
| Protein Folding | 4 | 2019 | 218 | 0.200 |
Why?
|
| Glycine | 1 | 2003 | 168 | 0.190 |
Why?
|
| Protein Structure, Quaternary | 3 | 2013 | 98 | 0.190 |
Why?
|
| Mice, Inbred BALB C | 1 | 2024 | 1008 | 0.190 |
Why?
|
| Mutagenesis, Site-Directed | 5 | 2019 | 317 | 0.180 |
Why?
|
| Candida albicans | 1 | 2021 | 76 | 0.180 |
Why?
|
| Histones | 2 | 2016 | 534 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 7 | 2011 | 1018 | 0.180 |
Why?
|
| Interferometry | 1 | 2020 | 26 | 0.180 |
Why?
|
| Ferritins | 1 | 2021 | 97 | 0.170 |
Why?
|
| Endothelium | 1 | 2020 | 72 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 196 | 0.170 |
Why?
|
| Candidiasis | 1 | 2021 | 129 | 0.170 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 134 | 0.170 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2015 | 52 | 0.170 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 112 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2024 | 541 | 0.170 |
Why?
|
| Amino Acid Substitution | 5 | 2019 | 393 | 0.170 |
Why?
|
| von Willebrand Disease, Type 2 | 1 | 2019 | 3 | 0.170 |
Why?
|
| Proteostasis Deficiencies | 1 | 2019 | 5 | 0.170 |
Why?
|
| Thrombophilia | 1 | 2020 | 43 | 0.170 |
Why?
|
| Endothelial Cells | 5 | 2024 | 527 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 298 | 0.170 |
Why?
|
| Cells, Cultured | 9 | 2017 | 3061 | 0.160 |
Why?
|
| Casein Kinase I | 1 | 2019 | 12 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2021 | 183 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 254 | 0.160 |
Why?
|
| Lipopolysaccharides | 2 | 2024 | 294 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 1691 | 0.150 |
Why?
|
| Publishing | 1 | 2020 | 109 | 0.150 |
Why?
|
| Extracellular Matrix | 1 | 1999 | 234 | 0.150 |
Why?
|
| Pandemics | 3 | 2022 | 1104 | 0.150 |
Why?
|
| Surface Plasmon Resonance | 4 | 2006 | 46 | 0.150 |
Why?
|
| Hemolytic-Uremic Syndrome | 2 | 2015 | 35 | 0.150 |
Why?
|
| Receptors, Collagen | 3 | 2004 | 7 | 0.150 |
Why?
|
| Crotalid Venoms | 4 | 2011 | 6 | 0.140 |
Why?
|
| Munc18 Proteins | 1 | 2017 | 20 | 0.140 |
Why?
|
| Biomechanical Phenomena | 3 | 2019 | 243 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 196 | 0.140 |
Why?
|
| Calcineurin | 1 | 2017 | 102 | 0.130 |
Why?
|
| Mutation | 10 | 2017 | 5814 | 0.130 |
Why?
|
| Protein Phosphatase 2C | 1 | 2016 | 55 | 0.130 |
Why?
|
| Male | 12 | 2024 | 61302 | 0.130 |
Why?
|
| HEK293 Cells | 4 | 2019 | 753 | 0.130 |
Why?
|
| Integrin alpha2 | 1 | 2015 | 9 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1709 | 0.120 |
Why?
|
| Microscopy, Atomic Force | 3 | 2009 | 14 | 0.120 |
Why?
|
| Collagen Type I | 2 | 2006 | 112 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 824 | 0.120 |
Why?
|
| Hemolysis | 1 | 2015 | 110 | 0.120 |
Why?
|
| Thermodynamics | 3 | 2010 | 144 | 0.120 |
Why?
|
| Cloning, Molecular | 4 | 2003 | 892 | 0.120 |
Why?
|
| Apolipoprotein E4 | 1 | 2015 | 44 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 1675 | 0.120 |
Why?
|
| Thrombin | 2 | 2017 | 60 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 273 | 0.120 |
Why?
|
| Female | 11 | 2024 | 66575 | 0.120 |
Why?
|
| Receptors, LDL | 1 | 2015 | 89 | 0.110 |
Why?
|
| Bleeding Time | 1 | 2014 | 8 | 0.110 |
Why?
|
| Actins | 1 | 2016 | 342 | 0.110 |
Why?
|
| Flow Cytometry | 3 | 2014 | 803 | 0.110 |
Why?
|
| Chromatography, Gel | 2 | 2010 | 97 | 0.110 |
Why?
|
| Cricetinae | 7 | 2009 | 414 | 0.110 |
Why?
|
| Shiga Toxin 1 | 1 | 2013 | 1 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 372 | 0.110 |
Why?
|
| Multiple Organ Failure | 1 | 2015 | 141 | 0.110 |
Why?
|
| Amino Acid Sequence | 8 | 2019 | 2705 | 0.110 |
Why?
|
| Complement Factor H | 1 | 2013 | 21 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 241 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3447 | 0.110 |
Why?
|
| Point Mutation | 2 | 2006 | 348 | 0.100 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 122 | 0.100 |
Why?
|
| Cytoskeleton | 1 | 2014 | 178 | 0.100 |
Why?
|
| CHO Cells | 6 | 2009 | 157 | 0.100 |
Why?
|
| Serum Albumin | 1 | 2013 | 110 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 538 | 0.100 |
Why?
|
| Stroke | 2 | 2018 | 984 | 0.100 |
Why?
|
| Catalytic Domain | 2 | 2009 | 157 | 0.100 |
Why?
|
| Edetic Acid | 2 | 2003 | 24 | 0.100 |
Why?
|
| Molecular Sequence Data | 8 | 2013 | 3882 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1272 | 0.100 |
Why?
|
| Lipid Bilayers | 1 | 2011 | 46 | 0.100 |
Why?
|
| DNA Primers | 2 | 2007 | 660 | 0.090 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 568 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 776 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2022 | 2626 | 0.090 |
Why?
|
| Base Sequence | 3 | 2007 | 3100 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2005 | 263 | 0.090 |
Why?
|
| Hemorheology | 2 | 2008 | 25 | 0.090 |
Why?
|
| Serum Albumin, Bovine | 1 | 2010 | 48 | 0.090 |
Why?
|
| Signal Transduction | 4 | 2016 | 4543 | 0.090 |
Why?
|
| Protein Phosphatase 1 | 1 | 2009 | 51 | 0.080 |
Why?
|
| Hemoglobin A | 1 | 2009 | 22 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2009 | 1527 | 0.080 |
Why?
|
| Cattle | 1 | 2010 | 566 | 0.080 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 205 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2021 | 3288 | 0.080 |
Why?
|
| Apoptosis | 1 | 2015 | 1792 | 0.080 |
Why?
|
| Heart-Assist Devices | 1 | 2017 | 1053 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 632 | 0.070 |
Why?
|
| Mass Spectrometry | 2 | 2019 | 331 | 0.070 |
Why?
|
| Substrate Specificity | 2 | 2009 | 290 | 0.070 |
Why?
|
| Magnesium Sulfate | 1 | 2008 | 50 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 3 | 2012 | 2425 | 0.070 |
Why?
|
| Mexico | 2 | 2020 | 180 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2015 | 910 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 200 | 0.070 |
Why?
|
| Collagen Type III | 1 | 2006 | 21 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2021 | 592 | 0.060 |
Why?
|
| Transfection | 4 | 2017 | 1069 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 1022 | 0.060 |
Why?
|
| Escherichia coli | 3 | 1999 | 987 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2013 | 869 | 0.060 |
Why?
|
| Mutagenesis | 2 | 2000 | 348 | 0.060 |
Why?
|
| Microspheres | 2 | 2008 | 71 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2009 | 339 | 0.060 |
Why?
|
| COS Cells | 2 | 2003 | 276 | 0.060 |
Why?
|
| Spectrum Analysis | 1 | 2005 | 62 | 0.060 |
Why?
|
| Antibody Affinity | 1 | 2004 | 39 | 0.060 |
Why?
|
| Fibrillar Collagens | 1 | 2004 | 15 | 0.060 |
Why?
|
| Hydrolases | 1 | 2024 | 58 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 106 | 0.060 |
Why?
|
| Polystyrenes | 2 | 2003 | 13 | 0.060 |
Why?
|
| Umbilical Veins | 2 | 2003 | 73 | 0.050 |
Why?
|
| Optics and Photonics | 1 | 2005 | 139 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2019 | 1626 | 0.050 |
Why?
|
| Receptor Aggregation | 1 | 2003 | 7 | 0.050 |
Why?
|
| Sulfoglycosphingolipids | 1 | 2003 | 8 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2016 | 58 | 0.050 |
Why?
|
| Immunoassay | 1 | 2003 | 130 | 0.050 |
Why?
|
| Hemagglutinins | 1 | 2003 | 23 | 0.050 |
Why?
|
| Swine | 2 | 2024 | 1173 | 0.050 |
Why?
|
| Reference Values | 1 | 2004 | 713 | 0.050 |
Why?
|
| Crystallography, X-Ray | 2 | 2002 | 357 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2003 | 99 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 661 | 0.050 |
Why?
|
| Time Factors | 4 | 2008 | 6311 | 0.050 |
Why?
|
| Arginine | 1 | 2024 | 331 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2024 | 578 | 0.050 |
Why?
|
| Capillary Leak Syndrome | 1 | 2021 | 3 | 0.050 |
Why?
|
| Acute-Phase Reaction | 1 | 2021 | 12 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2021 | 73 | 0.050 |
Why?
|
| Th17 Cells | 1 | 2021 | 90 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2003 | 436 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2021 | 187 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 93 | 0.040 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 46 | 0.040 |
Why?
|
| Coronavirus | 1 | 2020 | 25 | 0.040 |
Why?
|
| Cations, Divalent | 1 | 1999 | 20 | 0.040 |
Why?
|
| Middle Aged | 4 | 2020 | 26727 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 1999 | 186 | 0.040 |
Why?
|
| Molecular Conformation | 2 | 2011 | 101 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2002 | 359 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2021 | 143 | 0.040 |
Why?
|
| Disulfides | 2 | 2003 | 78 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 549 | 0.040 |
Why?
|
| Protein Stability | 2 | 2010 | 165 | 0.040 |
Why?
|
| Cations | 1 | 2019 | 39 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 693 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2019 | 129 | 0.040 |
Why?
|
| Risk Factors | 2 | 2022 | 10272 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 1046 | 0.040 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 145 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2000 | 224 | 0.040 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2018 | 31 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 145 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 1290 | 0.040 |
Why?
|
| Protein Denaturation | 2 | 2009 | 51 | 0.040 |
Why?
|
| Cell Line | 3 | 2010 | 2771 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 768 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2021 | 435 | 0.040 |
Why?
|
| Adult | 4 | 2017 | 29482 | 0.040 |
Why?
|
| Urea | 2 | 2009 | 227 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2019 | 356 | 0.030 |
Why?
|
| Histamine | 1 | 2017 | 44 | 0.030 |
Why?
|
| Models, Biological | 3 | 2008 | 1461 | 0.030 |
Why?
|
| Talin | 1 | 2016 | 8 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 137 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 485 | 0.030 |
Why?
|
| Peptides | 2 | 2016 | 794 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 459 | 0.030 |
Why?
|
| Shiga Toxins | 1 | 2015 | 2 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2016 | 122 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 1196 | 0.030 |
Why?
|
| Complement Inactivating Agents | 1 | 2015 | 12 | 0.030 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2015 | 20 | 0.030 |
Why?
|
| Thromboplastin | 1 | 2015 | 17 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 2015 | 58 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 282 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 701 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2017 | 468 | 0.030 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2013 | 6 | 0.030 |
Why?
|
| Enterohemorrhagic Escherichia coli | 1 | 2013 | 8 | 0.030 |
Why?
|
| Electrochemistry | 1 | 2013 | 23 | 0.030 |
Why?
|
| Protein Kinase C-alpha | 1 | 2013 | 19 | 0.030 |
Why?
|
| Glycosylation | 1 | 1993 | 119 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2013 | 40 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2013 | 250 | 0.030 |
Why?
|
| Perfusion | 2 | 2004 | 203 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 676 | 0.030 |
Why?
|
| Macaca fascicularis | 2 | 2005 | 87 | 0.020 |
Why?
|
| Triglycerides | 1 | 2015 | 573 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 1992 | 152 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 867 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 1992 | 59 | 0.020 |
Why?
|
| Heparin | 1 | 1993 | 229 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 315 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2011 | 49 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1252 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 2013 | 196 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 3143 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 504 | 0.020 |
Why?
|
| Phospholipids | 1 | 2011 | 106 | 0.020 |
Why?
|
| Blood Viscosity | 1 | 2011 | 13 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 1110 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 292 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 19693 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2016 | 1027 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 2539 | 0.020 |
Why?
|
| Solutions | 1 | 2010 | 65 | 0.020 |
Why?
|
| Receptors, Thrombin | 1 | 2009 | 12 | 0.020 |
Why?
|
| Secretory Vesicles | 1 | 2009 | 19 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2009 | 41 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1992 | 463 | 0.020 |
Why?
|
| Cricetulus | 1 | 2009 | 97 | 0.020 |
Why?
|
| Epitopes | 2 | 2004 | 431 | 0.020 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2009 | 6 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 64 | 0.020 |
Why?
|
| Enzyme Repression | 1 | 2009 | 4 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2009 | 86 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2009 | 200 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2009 | 229 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2009 | 163 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6522 | 0.020 |
Why?
|
| Antibodies, Blocking | 1 | 2009 | 61 | 0.020 |
Why?
|
| Temperature | 1 | 2009 | 305 | 0.020 |
Why?
|
| Cell Shape | 1 | 2008 | 61 | 0.020 |
Why?
|
| Magnesium | 1 | 2008 | 121 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 488 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 2006 | 86 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 286 | 0.020 |
Why?
|
| DNA | 1 | 1992 | 1604 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2006 | 426 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 3754 | 0.020 |
Why?
|
| Biophysical Phenomena | 1 | 2005 | 39 | 0.020 |
Why?
|
| Biophysics | 1 | 2005 | 50 | 0.010 |
Why?
|
| Valine | 1 | 2004 | 113 | 0.010 |
Why?
|
| Amino Acids | 1 | 2006 | 665 | 0.010 |
Why?
|
| Adhesiveness | 1 | 2003 | 12 | 0.010 |
Why?
|
| Leucine | 1 | 2004 | 311 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 2002 | 58 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 782 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 185 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 582 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 536 | 0.010 |
Why?
|
| Papio | 1 | 1997 | 60 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1997 | 117 | 0.010 |
Why?
|
| Calcium | 1 | 1997 | 1099 | 0.010 |
Why?
|